TOP TEN perturbations for 1552553_a_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552553_a_at
Selected probe(set): 1552553_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552553_a_at (1552553_a_at) across 6593 perturbations tested by GENEVESTIGATOR:

F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-4.9824514
Number of Samples:4 / 6
Experimental F. tularensis study 1 (novicida)
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

LPS study 4 / mock treated MONO-MAC-6 cell sample

Relative Expression (log2-ratio):3.3982677
Number of Samples:2 / 2
Experimental LPS study 4
MONO-MAC-6 (MM6) cells were treated with 10 ng/ml lipopolysaccharide (LPS). ATC code:---
Control mock treated MONO-MAC-6 cell sample
MONO-MAC-6 (MM6) cells mock treated.

Langerhans cell histiocytosis study 1 / normal epidermal Langerhans cell sample

Relative Expression (log2-ratio):3.2833633
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal epidermal Langerhans cell sample
Normal epidermal Langerhans cells were isolated from skin of healthy adult donors. Single cells were isolated by collagenase digestion from epidermal sheets and CD1a - expressing cells were isolated by FACS purification. Gene-chips were further analyzed for transcripts of potentially contaminating cells - no transcripts for CD3ε (T cell), CD19 (B cell) or Desmogleins 1-4 (keratinocytes) were detected, confirming purity of sorted cells.

E. coli study 1 / unstimulated, normal monocyte-derived macrophage sample

Relative Expression (log2-ratio):-3.262436
Number of Samples:12 / 16
Experimental E. coli study 1
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli.
Control unstimulated, normal monocyte-derived macrophage sample
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated.

pediatric meningococcal sepsis study 1 (24h; blood) / normal blood sample

Relative Expression (log2-ratio):3.182251
Number of Samples:3 / 3
Experimental pediatric meningococcal sepsis study 1 (24h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 24 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

Langerhans cell histiocytosis study 1 / normal plasmocytoid dendritic cell sample

Relative Expression (log2-ratio):3.1162214
Number of Samples:7 / 3
Experimental Langerhans cell histiocytosis study 1
Langerhans cell histiocytes (LCH) were isolated from LCH lesions of patients undergoing surgery. All patients had single system disease, five patients had bone lesion, one had skin lesion and one had mucosal manifestation. Langerhans cells histiocytes were purified by FACS as CD1a+ / CD270 + population with > 95% purity.
Control normal plasmocytoid dendritic cell sample
Normal plasmocytoid dendritic cells were isolated from peripheral blood of healthy adult donors. Plasmocytoid dendritic cells were defined as HLA-DR+ / CD45RAhi / CD11c- / BDCA2+ population.

ALL study 2 (33d) / ALL study 2 (0d)

Relative Expression (log2-ratio):3.0073519
Number of Samples:58 / 129
Experimental ALL study 2 (33d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken 33 days after remission-induction therapy (RIT).
Control ALL study 2 (0d)
Bone marrow samples from children with de novo acute lymphoblastic leukemia. Samples were taken before remission-induction therapy (RIT).

pediatric septic shock study 3 (school-age) / normal blood sample (school-age)

Relative Expression (log2-ratio):2.8337936
Number of Samples:22 / 9
Experimental pediatric septic shock study 3 (school-age)
Whole blood obtained from scholar age children (> 6 years of age) with septic shock. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. To determine survival rate, patients were followed for 28 days.
Control normal blood sample (school-age)
Whole blood samples from school-age children (≥ 6 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.

pediatric meningococcal sepsis study 1 (72h; blood) / normal blood sample

Relative Expression (log2-ratio):2.740531
Number of Samples:2 / 3
Experimental pediatric meningococcal sepsis study 1 (72h; blood)
Blood samples collected from children with (suspected) meningococcal sepsis 72 hours after admission to the pediatric intensive care unit (PICU).
Control normal blood sample
Normal blood samples collected from healthy children admitted for elective minor non-infectious surgery or MRI.

pediatric septic shock study 3 (toddler; subclass B) / normal blood sample (toddler)

Relative Expression (log2-ratio):2.728674
Number of Samples:15 / 18
Experimental pediatric septic shock study 3 (toddler; subclass B)
Whole blood samples obtained from toddlers (2 – 5 years) with septic shock subclass B. The samples were obtained within 24 hours of admission to the pediatric intensive care unit. Two children did not survive. The subclass B was defined based on an empiric, discovery oriented expression filter and unsupervised hierarchical clustering. Patients in subclass B (when all age groups were pooled) had an illness severity level (PRISM III score) 15 (intra-quartile range (IQR) 10.0 - 21.0), maximum number of organ failures 2 (IQR 2 - 3), and an intermediate mortality rate. A significantly greater proportion of patients in subclass B received hydrocortisone for cardiovascular shock.
Control normal blood sample (toddler)
Whole blood samples from toddlers (2 – 5 years). Children who had a recent febrile illness (within 2 weeks), who recently used anti-inflammatory medications (within 2 weeks) or who had any history of chronic or acute disease associated with inflammation were excluded from the study.